Atherosclerosis severity is not affected by a deficiency in il-33/st2 signaling

Immunity, Inflammation and Disease

Volumn 3, Issue 3, 2015, Pages 239-246

  Martin, Praxedis ^a,b   Palmer, Gaby ^a,b   Rodriguez, Emiliana ^a,b   Woldt, Estelle ^a,b   Mean, Isabelle ^a,b   James, Richard W ^a   Smith, Dirk E ^c   Kwak, Brenda R ^a,b   Gabay, Cem ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c AMGEN INC   (United States)

Author keywords

Atherosclerosis; IL 33; ST2; Th1 to Th2 shift

Indexed keywords

EID: 84965159631     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.62     Document Type: Article

References (27)

1. Palmer, G., and C. Gabay. 2011. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 7:321–329.
2. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, and X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490.
3. Moussion, C., N. Ortega, and J. P. Girard. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ’alarmin’? PLoS One 3:e3331.
4. Pichery, M., E. Mirey, P. Mercier, E. Lefrancais, A. Dujardin, N.S Ortega, and J.P. Girard. 2012. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 188:3488–3495.
5. Mirchandani, A. S., A. G. Besnard, E. Yip, C. Scott, C. C. Bain, V. Cerovic, R. J. Salmond, and F. Y. Liew. 2014. Type 2 innate lymphoid cells drive CD4+ Th2 cell responses. J Immunol 192:2442–2448.
6. Moritz, D. R., H. R. Rodewald, J. Gheyselinck, and R. Klemenz. 1998. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 161:4866–4874.
7. Lohning, M., A. Stroehmann, A. J. Coyle, J. L. Grogan, S. Lin, J. C. Gutierrez-Ramos, D. Levinson, A. Radbruch, and T. Kamradt. 1998. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 95:6930–6935.
8. Yla-Herttuala, S., J. F. Bentzon, M. Daemen, E. Falk, H. M. Garcia-Garcia, J. Herrmann, I. Hoefer, S. Jauhiainen, J. W. Jukema, and R. Krams, et al. 2013. Stabilization of atherosclerotic plaques: an update. Eur Heart J 34:3251–3258.
9. Miller, A. M., D. L. Asquith, A. J. Hueber, L. A. Anderson, W. M. Holmes, A. N. McKenzie, D. Xu, N. Sattar, I. B. McInnes, and F. Y. Liew. 2010. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 107:650–658.
10. Hasan, A., F. Al-Ghimlas, S. Warsame, A. Al-Hubail, R. Ahmad, A. Bennakhi, M. Al-Arouj, K. Behbehani, M. Dehbi, and S. Dermime. 2014. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol 15:19.
11. Miller, A. M., D. Xu, D. L. Asquith, L. Denby, Y. Li, N. Sattar, A. H. Baker, I. B. McInnes, and F. Y. Liew. 2008. IL-33 reduces the development of atherosclerosis. J Exp Med 205:339–346.
12. Ngoi, S. M., M. C. St Rose, A. M. Menoret, D. E. Smith, M. G. Tovey, A. J. Adler, and A. T. Vella. 2012. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci USA 109:10486–10491.
13. Beamer, C. A., T. A. Girtsman, B.P. Seaver, K. J. Finsaas, C. T. Migliaccio, V.K. Perry, J.B. Rottman, D. E. Smith, and A. Holian. 2013. IL-33 mediates multi-walled carbon nanotube (MWCNT)-induced airway hyper-reactivity via the mobilization of innate helper cells in the lung. Nanotoxicology 7:1070–1081.
14. Danzaki, K., Y. Matsui, M. Ikesue, D. Ohta, K. Ito, M. Kanayama, D. Kurotaki, J. Morimoto, Y. Iwakura, and H. Yagita, et al. 2012. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 32:273–280.
15. Stepankova, R., Z. Tonar, J. Bartova, L. Nedorost, P. Rossman, R. Poledne, M. Schwarzer, and H. Tlaskalova-Hogenova. 2010. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb 17:796–804.
16. Kondo, Y., T. Yoshimoto, K. Yasuda, S. Futatsugi-Yumikura, M. Morimoto, N. Hayashi, T. Hoshino, J. Fujimoto, and K Nakanishi. 2008. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 20:791–800.
17. Sweet, M. J., B. P. Leung, D. Kang, M. Sogaard, K. Schulz, V. Trajkovic, C. C. Campbell, D. Xu, and F. Y. Liew. 2001. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 166:6633–6639.
18. Martin, P., D. Talabot-Ayer, C. A. Seemayer, S. Vigne, C. Lamacchia, E. Rodriguez, A. Finckh, D. E. Smith, C. Gabay, and G. Palmer. 2013. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther 15:R13.
19. Hoshino, K., S. Kashiwamura, K. Kuribayashi, T. Kodama, T. Tsujimura, K. Nakanishi, T. Matsuyama, K. Takeda, and S. Akira. 1999. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med 190:1541–1548.
20. Coyle, A. J., C. Lloyd, J. Tian, T. Nguyen, C. Erikkson, L. Wang, P. Ottoson, P. Persson, T. Delaney, and S. Lehar, et al. 1999. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 190:895–902.
21. Mangan, N. E., A. Dasvarma, A. N. McKenzie, and P. G. Fallon. 2007. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol 37:1302–1312.
22. Oboki, K., T. Ohno, N. Kajiwara, K. Arae, H. Morita, A. Ishii, A. Nambu, T. Abe, H. Kiyonari, and K. Matsumoto, et al. 2010. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 107:18581– 18586.
23. Maeda, N., L. Johnson, S. Kim, J. Hagaman, M. Friedman, and R. Reddick. 2007. Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds. Atherosclerosis 195: 75–82.
24. Paigen, B., A. Morrow, C. Brandon, D. Mitchell, and P. Holmes. 1985. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57:65–73.
25. Hashmi, S., and Q. T. Zeng. 2006. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleu-kin-8 in unstable coronary artery disease. Coron Artery Dis 17:699–706.
26. Townsend, M. J., P. G. Fallon, D. J. Matthews, H. E. Jolin, and A. N. McKenzie. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 191:1069–1076.
27. James, R. W., and D. Pometta. 1990. Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 39:1158–1164.